Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
501 to 520 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| R01HL113326 | Characterization of European American and African American Sarcoidosis via Immunogenetics | 1 | 2022 |
| R01HL117004 | The Airway Functional Genomics of Bronchodilator Drug Response in Minority Children with Asthma | 1 | 2022 |
| R01HL126527 | Genome Editing of Human iPSCs to Study Inherited Hypertrophic Cardiomyopathy | 1 | 2022 |
| R01HL140961 | Hyperglycemia mediated myeloproliferative disease | 1 | 2022 |
| R01HL141845 | Poly-omic Study of Asthma Exacerbations in Diverse Populations | 1 | 2022 |
| R01HL141852 | Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis | 1 | 2022 |
| R01HL147148 | Genetic and Functional Dissection of a Cluster of COPD GWAS Signals on Chromosome 4q | 1 | 2022 |
| R01HL148821 | IDENTIFICATION AND PRECLINICAL EVALUATION OF NOVEL THERAPEUTIC APPROACHES TO DYSKERATOSIS CONGENITA | 1 | 2022 |
| R01HL149303 | Pathological flow-induced endothelial damage and plaque erosion | 1 | 2022 |
| R01LM010685 | Beyond PheWAS: Recognition of Phenotype Patterns for Discovery and Translation | 1 | 2022 |
| R01NS102371 | Integrating Common and Rare Variation to Discover Genes Associated with Tourette Syndrome | 1 | 2022 |
| R21AI157909 | Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection | 1 | 2022 |
| R21CA256648 | Genetic Biomarkers for Risk of CLL Progression among high-count MBLs | 1 | 2022 |
| R21CA264637 | Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolution | 1 | 2022 |
| R35CA209919 | LncRNA mechanisms in cancer | 1 | 2022 |
| R35GM118088 | Dynamics of RNA-protein interactions | 1 | 2022 |
| T32GM008490 | Predoctoral Training Program in Genetics | 1 | 2022 |
| T32GM080189 | The Chemistry-Biology Interface Program at Johns Hopkins University | 1 | 2022 |
| T32HL139451 | Cardiovasomobility Research Training Program | 1 | 2022 |
| TL1TR002493 | NRSA Training Core | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=26